Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing
Viking Therapeutics Inc. shares picked up 1.7% to $32.19 on Thursday afternoon. Lake Street rolled out new coverage with a bullish call on the obesity-drug company. The stock moved in a range of $31.39 to $32.22. Market cap was around $3.72 billion. Viking remains a clinical-stage drugmaker, with most of its worth tied to treatments in development rather than products on the market. Investors are looking at its obesity drug VK2735, now heading for Phase 3 trials, to see if it can make it through the final testing needed for approval as obesity treatments keep moving toward oral and injectable options.